Research institutionFrancearcagy.org
ARCAGY-GINECO is an independent, non-profit academic cooperative research group specializing in clinical and translational research focused on gynecological cancers and metastatic breast cancer.
Founded in 1993, the organization designs, promotes, coordinates, and conducts clinical trials in France and internationally to advance therapeutic standards, improve patient survival, and enhance quality of life. It maintains its own operational infrastructure with dedicated teams for clinical operations, regulatory affairs, translational research, and administration.
ARCAGY-GINECO is labeled by the French National Cancer Institute (INCa) as an intergroup of international dimension and receives support from the Ligue Nationale contre le Cancer. It serves as a leading member of the European Network for Gynaecological Oncological Trial groups (ENGOT), frequently acting as the lead group for multinational trials, and participates in the Gynecologic Cancer InterGroup (GCIG).
Headquartered in Paris, France, the group has coordinated more than 200 research programs involving over 16,500 patients across more than 400 partner centers worldwide. Its work has resulted in over 1,000 scientific publications and contributes significantly to evidence-based advancements in gynecological oncology.
Also known as Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens et du sein.
None yet. When a new project in the record names GINECO as owner, partner or investor, it shows here.
Sofe‑M plus bevacizumab produced a 79% confirmed objective response rate and 100% disease control in platinum‑sensitive ovarian cancer, with activity across FRα levels and prior PARPi exposure.
